Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.
Publication
, Journal Article
Pokorney, SD; Shrader, P; Thomas, L; Fonarow, GC; Kowey, PR; Singer, DE; Ansell, J; Gersh, BJ; Mahaffey, KW; Hylek, EM; Go, AS; Piccini, JP ...
Published in: Circulation
October 11, 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
October 11, 2016
Volume
134
Issue
15
Start / End Page
1122 / 1124
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Thiazoles
- Registries
- Pyridines
- Prospective Studies
- Male
- Kidney Function Tests
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Pokorney, S. D., Shrader, P., Thomas, L., Fonarow, G. C., Kowey, P. R., Singer, D. E., … Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. (2016). Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 134(15), 1122–1124. https://doi.org/10.1161/CIRCULATIONAHA.116.024333
Pokorney, Sean D., Peter Shrader, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Daniel E. Singer, Jack Ansell, et al. “Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.” Circulation 134, no. 15 (October 11, 2016): 1122–24. https://doi.org/10.1161/CIRCULATIONAHA.116.024333.
Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, et al. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11;134(15):1122–4.
Pokorney, Sean D., et al. “Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.” Circulation, vol. 134, no. 15, Oct. 2016, pp. 1122–24. Pubmed, doi:10.1161/CIRCULATIONAHA.116.024333.
Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11;134(15):1122–1124.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
October 11, 2016
Volume
134
Issue
15
Start / End Page
1122 / 1124
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Thiazoles
- Registries
- Pyridines
- Prospective Studies
- Male
- Kidney Function Tests
- Humans
- Female